Your signal. Your price.
Brown argues there is a revolving door between pharmaceutical executives and agencies like the FDA, with no equivalent to the military-industrial complex's cooling-off period. This influences policy and media coverage.
Max Hodak notes Europe uses a notified body system for certification, where private firms compete to review products, creating more reviewers and slightly better incentives than the US's monolithic FDA.
Andrew Huberman frames peptides as FDA-approved drugs like GLP-1 agonists (Ozempic, Mounjaro) and research compounds like BPC-157, which have minimal human studies but long anecdotal use for gut health and tissue repair.
Bakri notes the LD50 for BPC-157 is unknown, complicating FDA approval, and the primary safety concern is its potential to promote angiogenesis (VEGF signaling), which could theoretically fuel tumors, though no such signal exists in animal data.
Only 4 results for these filters — try broadening your search